Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pituitary adenylate cyclase-activating polypeptide siRNA
- Development stage
- Preclinical
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Pituitary adenylate cyclase-activating polypeptide (PACAP) siRNA is a small interfering RNA designed to selectively silence the expression of the ADCYAP1 gene, which encodes the PACAP neuropeptide. PACAP is a neuropeptide involved in immune and fibrotic regulation, and its upregulation has been implicated in chronic inflammatory conditions such as Hunner-type interstitial cystitis (HIC). In preclinical models, transfection with PACAP siRNA downregulates proinflammatory cytokines (such as IL-6, IL-1β, and TNF-α) and profibrotic mediators, thereby reducing cell proliferation and migration. This siRNA is primarily utilized as a research reagent to investigate the role of PACAP in inflammatory and fibrotic pathways.
- Other names
- ADCYAP1 siRNAADCYAP-1 siRNAADCYAP 1 siRNAPACAP siRNApituitary adenylate cyclase-activating polypeptide small interfering RNA
02
Targets
PACAP (Pituitary adenylate cyclase-activating polypeptide)
Beyond the preview
Go deeper on pituitary adenylate cyclase-activating polypeptide siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pituitary adenylate cyclase-activating polypeptide siRNA.